PHASE-I TRIAL OF A NEW FORM OF AN ORAL-ADMINISTRATION OF VP-16-213
- 1 January 1979
- journal article
- research article
- Vol. 63 (3) , 485-487
Abstract
A new oral form of VP-16-213 [4''-demethylepipodophyllotoxin-.beta.-D-ethylidene] consisting of a hydrophilic soft gelatin capsule containing a VP-16-213 solution was tested for toxicity in 26 cancer patients. The drug was administered at 4 different dose levels, 350, 500, 650 and 750 mg/m2, in 5-day courses every 21-28 days. A dose-dependent effect was observed with regard to hematologic toxicity and alopecia. The drinking ampules of VP-16-213 can be replaced with the new oral capsules with a recommended initial dose of 100-130 mg/m2 given in 5-day courses every 21-28 days.This publication has 3 references indexed in Scilit:
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- PHASE I CLINICAL-TRIAL OF AN ORAL SOLUTION OF VP-16-2131976